{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:45Z","timestamp":1790192805248,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"s12","license":[{"start":{"date-parts":[[2004,6,24]],"date-time":"2004-06-24T00:00:00Z","timestamp":1088035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Introduction:\u2002<\/jats:bold> Conversion from calcineurin inhibitor (CI)\u2010based maintenance immunosuppression to sirolimus (SRL)\u2010based immunosuppression may be beneficial in selected renal transplant recipients. The purpose of this study was to evaluate the safety and efficacy of a daclizumab (DAC) bridge protocol in patients converted from CI\u2010 to SRL\u2010based maintenance immunosuppression.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> We conducted a retrospective chart review of renal transplant recipients who were converted to SRL at least 2\u2003months post\u2010transplant. The protocol consisted of an abrupt discontinuation of either cyclosporin (CsA) or tacrolimus (TAC), initiation of SRL within 48\u2003h of CI discontinuation, and DAC 2\u2003mg\/kg at the time of CI discontinuation and again at 14\u2003d (depending on the SRL serum concentration). The SRL starting dose was based on risk stratification in each patient.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Twenty\u2010one renal transplant patients were converted to SRL (11 from TAC, 10 from CsA) between October 2001 and July 2003. Conversion occurred at a mean of 23\u2003months post\u2010transplant. Indications for SRL conversion included 12 for chronic allograft nephropathy (CAN), four for CI\u2010associated neurotoxicity, two for thrombotic microangiopathy (TMA), two for post\u2010transplant diabetes mellitus (PTDM), and one for polyomavirus interstitial nephritis (PVN). Mean follow\u2010up was 16\u2003months from time of conversion. Therapeutic SRL levels were reached at a mean of 14\u2003d. Total serum cholesterol levels increased from a mean of 205 (\u00b1\u200347) to 234 (\u00b1\u200355) mg\/dL (<jats:italic>P<\/jats:italic>\u2003<jats:italic>=<\/jats:italic>\u20030.014), and serum triglyceride levels increased from a mean of 186 (\u00b1\u200366) to 257 (\u00b1\u200388) mg\/dL (<jats:italic>P<\/jats:italic>\u2003<jats:italic>=<\/jats:italic>\u20030.002). In addition, mean haemoglobin level decreased from 12.0 (\u00b1\u20032.3) to 10.5 (\u00b1\u20032.1) g\/dL (<jats:italic>P<\/jats:italic>\u2003<jats:italic>=<\/jats:italic>\u20030.002); total white blood cell count decreased from 8300 (\u00b1\u20034300) to 4700 (\u00b1\u20031400)\/mm<jats:sup>3<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003<jats:italic>&lt;<\/jats:italic>\u20030.001); and platelet count decreased from 238\u2003000 (\u00b1\u200372\u2003800) to 186\u2003000 (\u00b1\u200351\u2003900)\/mm<jats:sup>3<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003<jats:italic>=<\/jats:italic>\u20030.002) from before to after conversion. Patients experienced the following side\u2010effects while taking SRL: diarrhoea (<jats:italic>n<\/jats:italic>\u2003=\u20036), peripheral oedema (<jats:italic>n<\/jats:italic>\u2003=\u20035), arthralgias (<jats:italic>n<\/jats:italic>\u2003=\u20034), anaemia (<jats:italic>n<\/jats:italic>\u2003=\u20034), oral ulcers (<jats:italic>n<\/jats:italic>\u2003=\u20031), deep vein thrombosis (<jats:italic>n<\/jats:italic>\u2003=\u20031), shortness of breath (<jats:italic>n<\/jats:italic>\u2003=\u20031), and mild increase in serum transaminases (<jats:italic>n<\/jats:italic>\u2003=\u20031). Two patients (9.5%) discontinued SRL due to side\u2010effects, both secondary to severe arthralgias. There were two serious infections noted after conversion: one <jats:italic>Pseudomonas aeruginosa<\/jats:italic> urosepsis, and one PVN (that was ongoing prior to conversion). Patient survival was 100%, and kidney graft survival was 76%. Five patients (24%) lost their allograft after conversion due to progression of CAN (<jats:italic>n<\/jats:italic>\u2003=\u20032), persistent TMA in the kidney (<jats:italic>n<\/jats:italic>\u2003=\u20031), patient self\u2010discontinuation of sirolimus (<jats:italic>n<\/jats:italic>\u2003=\u20031), and preexisting PVN unresponsive to cidofovir therapy (<jats:italic>n<\/jats:italic>\u2003=\u20031). Of the five patients who lost their allograft, the mean serum creatinine at the time of conversion was 3.5 (\u00b11.1) mg\/dL compared with 2.2 (\u00b1\u20030.8) mg\/dL in patients who did not lose their allograft (<jats:italic>P<\/jats:italic>\u2003<jats:italic>=<\/jats:italic>\u20030.034). No acute rejection episodes occurred after conversion to sirolimus.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> DAC bridge therapy provides safe and effective immunosuppressive coverage while converting renal transplant recipients from CI\u2010 to SRL\u2010based maintenance immunosuppressive therapy. A pharmacoeconomic analysis, however, is necessary to determine the cost\u2010effectiveness of this conversion protocol.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2004.00220.x","type":"journal-article","created":{"date-parts":[[2004,6,24]],"date-time":"2004-06-24T17:50:31Z","timestamp":1088099431000},"page":"61-66","source":"Crossref","is-referenced-by-count":20,"title":["Conversion to sirolimus\u2010based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients"],"prefix":"10.1111","volume":"18","author":[{"given":"Aimee K","family":"Sundberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Stratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,6,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605083141904"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199708150-00012"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70348-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00611.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590041567.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00240-9"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)02375-2"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00375-0"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2002.kid582.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1681\/ASN.V123583","article-title":"Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study","volume":"21","author":"Van Duijnhoven EM","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2000.tb01004.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V11101910"},{"key":"e_1_2_6_14_2","unstructured":"Rapamune\u00ae package insert.Wyeth Pharmaceuticals Collegeville PA USA 2003."},{"key":"e_1_2_6_15_2","unstructured":"Zenapax\u00ae (daclizumab) package insert.Roche Pharmaceuticals Nutley NJ USA 2003."},{"key":"e_1_2_6_16_2","volume-title":"Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.","author":"National Cholesterol Education Program.","year":"2002"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2004.00220.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2004.00220.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T09:53:02Z","timestamp":1695721982000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2004.00220.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,24]]},"references-count":15,"journal-issue":{"issue":"s12","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1399-0012.2004.00220.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2004.00220.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,24]]}}}